Pacritinib is a kinase inhibitor indicated for the treatment of adult patients with myelofibrosis, a rare bone marrow disorder characterized by ineffective blood cell production. This category includes… Read more
Pacritinib is a kinase inhibitor indicated for the treatment of adult patients with myelofibrosis, a rare bone marrow disorder characterized by ineffective blood cell production. This category includes the reference standard for the active pharmaceutical ingredient (API), along with associated process-related impurities such as the N-nitroso variant and stable isotope labelled compounds like Pacritinib-d4. Pharmaceutical laboratories require these high-quality materials for precise analytical testing, method validation, and rigorous quality control protocols. Impurity reference standards are essential for the accurate identification and quantification of contaminants during drug substance analysis to ensure patient safety. Additionally, stable isotope labelled compounds serve as critical internal standards in liquid chromatography-mass spectrometry (LC-MS/MS) applications, offering reliable performance for pharmacokinetic and bioanalytical studies. Together, these materials provide the benchmarks necessary for regulatory compliance and scientific integrity throughout the drug development and manufacturing lifecycle.